SCHEMBL1368142

SCHEMBL1368142

COc1ccc(/C=C/C(=O)CC(=O)c2cc3ccc(Cl)cc3[nH]c2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PADI4 Q9UM07 2/20 0.57
GSK3B P49841 1/20 0.52
PDGFRB P09619 1/20 0.47
FLT3 P36888 1/20 0.47
MAPT P10636 3/20 0.46
MAOB P27338 4/20 0.45
APP P05067 1/20 0.45
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
THPO P40225 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368149 1.00 PADI4 (0.57) PADI4GSK3BPDGFRBFLT3MAPT
SCHEMBL1368309 1.00 PADI4 (0.57) PADI4GSK3BPDGFRBFLT3MAPT
SCHEMBL1368303 0.91 DAO (0.46) PADI4MAPTMAOBRAB9AMEN1
SCHEMBL1366316 0.91 DAO (0.46) PADI4MAPTMAOBRAB9AMEN1
SCHEMBL1366313 0.91 DAO (0.46) PADI4MAPTMAOBRAB9AMEN1
SCHEMBL5823419 0.90 MAOB (0.47) PADI4GSK3BMAPTMAOBALDH1A1
SCHEMBL5823424 0.90 MAOB (0.47) PADI4GSK3BMAPTMAOBALDH1A1
SCHEMBL1366173 0.87 PADI4 (0.76) PADI4GSK3BMAPTMAOBAPP
SCHEMBL1365750 0.87 PADI4 (0.76) PADI4GSK3BMAPTMAOBAPP
SCHEMBL1365749 0.87 PADI4 (0.76) PADI4GSK3BMAPTMAOBAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS PADI4 3091/4885GSK3B 4183/4885PDGFRB 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.